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This mini review provides an overview of the issues and challenges inherent in autosomal 
recessive polycystic kidney disease (ARPKD), with a particular focus on the neurological 
factors and neurocognitive functioning of this population. ARPKD typically is discovered 
at the end of pregnancy or during the neonatal developmental period and occurs in 
approximately 1 in 20,000 live births. During the neonatal period, there is a relatively 
high risk of death, with many infants dying from respiratory failure. As the child ages, 
they experience progressive kidney disease and become increasingly vulnerable to liver 
disease, with many individuals eventually requiring dual organ transplants. This mini 
review provides a brief description of ARPKD and describes the various factors that 
place children with ARPKD at risk for neurological and neuropsychological impairment 
(e.g., a genetic condition leading to chronic kidney disease and eventual transplant; 
difficult-to-treat hypertension; eventual liver disease; possible dual transplantation of the 
kidneys and liver; chronic lung disease), including that these factors are present during 
a critical period of brain development. Further, the mini review discusses the available 
studies that have addressed the neurocognitive functioning in children with ARPKD. 
This paper concludes by providing the key clinical and research challenges that face 
the field of pediatric nephrology with respect to the clinical and scientific study of the 
neurocognitive functioning of children with ARPKD. Selected directions are offered in 
both the clinical and research arenas for this multiorgan chronic condition.
Keywords: autosomal recessive polycystic kidney disease, pediatric autosomal recessive polycystic kidney 
disease, neurocognition in autosomal recessive polycystic kidney disease, risk factors for neurocognitive 
dysfunction in autosomal recessive polycystic kidney disease, polycystic kidney diseases
inTRODUCTiOn
Cystic kidney diseases represent a heterogeneous group of renal conditions characterized by tubular 
cysts, glomerular cysts, or dysplasia. Within this heterogenous group, polycystic kidney disease 
typically refers to two conditions: autosomal dominant polycystic kidney disease (ADPKD) and 
autosomal recessive polycystic kidney disease (ARPKD), that are genetically distinct (1, 2). In 
most instances, these two conditions manifest in different developmental epochs, with the ARPKD 
being associated with younger children and ADPKD being associated with adults; however, given 
their genetic basis, both conditions can appear at any developmental time period. For this special 
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issue, a key focus has been placed on ARPKD and its various 
characteristics. The purpose of this paper is to address the state 
of the literature regarding the neurocognitive functions and 
associated neurodevelopmental issues and challenges presented 
by ARPKD.
ePiDeMiOLOGY AnD eARLY 
DeveLOPMenTAL COURSe OF ARPKD
Autosomal recessive polycystic kidney disease occurs at a lower 
frequency than its genetic counterpart, ADPKD, with incidence 
being about 1:20,000 live births (3), with rates ranging from 
1:6,000 to 1:55,000 (1, 4). Many affected infants may die during 
the neonatal period secondary to respiratory failure, suggesting 
that these incidence rates actually may underestimate the true 
number of individuals with ARPKD. In the past, a diagnosis of 
ARPKD was believed to be a fatal condition at birth, with infant 
death now estimated to be at approximately 23–30%. Those sur-
viving the neonatal period typically will have a 10-year survival 
rate of around 80% (5), with the risk of death secondary to liver 
disease increasing with age (6). Concomitantly, renal disease also 
advances, albeit slowly (7), with about 30% reaching end-stage 
renal disease before the age of 10 years, and another 30% during 
adolescence (8). Alarmingly, emergent data from individuals 
with ARPKD, who received a kidney transplant, suggest that 
approximately 80% subsequently developed liver disease, which 
not only complicated the kidney transplant but also increased the 
risk of death (6). There are no differences in incidence rates across 
gender or race/ethnicities.
Autosomal recessive polycystic kidney disease occurs from 
mutations in one gene, the Polycystic Kidney and Hepatic Disease 1 
gene (PKHD1). The PKHD1 gene encodes the fibrocystin protein 
whose functions remain unclear at this time. In most cases, this 
condition is uncovered during the end of pregnancy or during 
the neonatal period (9), with the infant manifesting significantly 
enlarged kidneys, progressive renal insufficiency, and arterial 
hypertension (2, 3), the latter being present in nearly 80% of 
infants. Further, many infants will show pulmonary insufficiency 
that can result in death in about one-third of afflicted infants. For 
nearly all infants, the early clinical presentation is characterized 
by kidney dysfunction and, as the child ages, disruptions of liver 
function (10). In general, this condition will manifest very early 
in development; however, a small subset of cases will manifest 
symptoms during later development, with symptoms being 
dominated by liver complications (11).
RiSK FACTORS FOR neUROCOGniTive 
DYSFUnCTiOn in ARPKD
There are multiple neurological conditions that can be associ-
ated with renal disease. These include central nervous system 
conditions such as uremic encephalopathy syndrome, seizures, 
movement disorders, and strokes—which can occur at alarming 
rates, sleep disorders, and a variety of peripheral nervous system 
conditions (e.g., polyneuropathy) (12). There are also neurologi-
cal symptoms that can be associated with dialysis procedures (13) 
and transplant (14). All of these neurological conditions can and 
will contribute to neurocognitive deficits and dysfunction in 
children with ARPKD. Additionally, children and adolescents 
with ARPKD have a number of other vulnerabilities that can 
contribute to the manifestation of various neurodevelopmental 
challenges, particularly cognitive difficulties.
Chronic Kidney Disease (CKD)
The mere fact that individuals evidence CKD places them at 
varying degrees of risk for neurocognitive and social–behavioral 
challenges throughout their life span (15). Approximately 40% 
of children and adolescents with mild-to-moderate CKD have 
been shown to exhibit some form of neurocognitive dysfunction, 
perhaps secondary to the associated cardiovascular risk and 
other factors associated with CKD (16). Although there are no 
clear data suggesting when children with ARPKD will progress 
to end-stage renal disease, or the factors that contribute to this 
progression in this population, many children with ARPKD 
ultimately may need renal replacement therapy. These therapies, 
particularly dialysis, can also contribute to the manifestation of 
neurocognitive difficulties. For example, for the youngest affected 
children, progression can be rapid and they may require dialysis 
early in life. It has been estimated that approximately 25% of 
very young children with severe renal difficulties will have signif-
icant developmental delays, and very young infants and toddlers 
with ARPKD on dialysis likely are similarly affected (17).
Hypertension
In conjunction with CKD, children with ARPKD also are at risk 
for hypertension. Although there are little extant data specific to 
children with ARPKD, there is growing evidence that primary 
hypertension (18–22), and even variability in blood pressure 
(23), are associated with altered neurocognition in children. 
The potential cause is unclear, though investigators have posited 
that chronic hypertension may result in small vessel damage, 
which, in turn, leads to reduced or impaired regulation of cer-
ebral blood flow (24) that can impact brain development over 
time. In particular, the development of executive functioning, a 
protracted process that extends into young adulthood, may be 
particularly vulnerable to alterations in the capacity of vessels to 
dilate in response to local or regional changes in neuronal activity 
(21). More specifically, elevated blood pressure and hypertension 
in children and adolescents have been associated with lower 
scores on performance-based measures of working memory, 
non-verbal reasoning, and aspects of academic achievement 
compared to individuals with normal pressure (22). Importantly, 
most documented differences have occurred within the normal 
range of functioning, and there is preliminary evidence that 
executive functioning may improve with antihypertensive treat-
ment (25). How these findings manifest in children with ARPKD 
remains to be determined, but the presence of early and sig-
nificant hypertension in ARPKD put these children at risk for 
neurocognitive disruption.
Hepatic Fibrosis
Another source of morbidity in children with ARPKD is hepatic 
fibrosis. With respect to the neurocognitive effects of liver disease, 
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there have been several case reports of hepatic encephalopathy 
in individuals with ARPKD who have undergone portosystemic 
shunting (PSS) to relieve severe portal hypertension in patients 
with isolated congenital hepatic fibrosis (26). In individuals 
with ARPKD and with renal dysfunction, hyperammonemia 
after PSS may exceed the capacity for renal ammonia disposal, 
resulting in hepatic encephalopathy in ARPKD patients with 
PSS on chronic hemodialysis (5), in the immediate postrenal 
transplant period (6) and following bilateral nephrectomy (27). 
While these cases illustrate the potential for overt encepha-
lopathy in ARPKD patients with PSS and advanced CKD, it 
is unknown whether patients with milder CKD could have 
subtle neurocognitive deficits following PSS. Further studies are 
therefore needed to detect whether “minimal hepatic encepha-
lopathy” (28) could occur in this population. For children with 
ARPKD needing a liver transplant, findings from pediatric 
liver transplantation in other non-ARPKD-specific popula-
tions suggest additional potential difficulties including lower 
quality of life (29, 30), poorer family functioning (31), lower 
self-perceptions of physical attractiveness, and depressed mood 
(32). In fact, these cognitive and psychosocial difficulties do not 
seem to improve following transplantation over the short-term 
or the long-term (33), thus raising another potential concern for 
neurodevelopmental difficulties in children with ARPKD and 
liver involvement.
Chronic Lung Disease
Finally, a third source of morbidity for children with ARPKD 
is chronic lung disease, particularly during the neonatal period 
and in those infants who are born prematurely. As noted ear-
lier, many affected infants may die during the neonatal period 
secondary to respiratory failure, but many infants survive only 
to experience bronchopulmonary dysplasia, or chronic lung 
disease. Chronic lung disease is an inflammatory disorder that 
tends to manifest in the first few weeks of life, with about 40% 
of infants with ARPKD requiring mechanical ventilation and 
pharmacological treatments for the lung disease (9). For pre-
mature infants with chronic lung disease who survive their first 
year of life, there may be downstream neurocognitive deficits that 
comprised developmental delays noted at 2 years of age (34) as 
well as later deficits in IQ, gross motor functions, visual-spatial 
abilities, and core reading and math skills in middle childhood 
(35, 36). Consequently, the manifestation of chronic lung disease 
in infants with ARPKD creates yet another risk factor for neu-
rodevelopmental difficulties as the child advances in age.
neUROCOGniTive FinDinGS in ARPKD
Given the neonatal risks that many individuals with ARPKD 
experience, the subsequent kidney function deterioration, 
hypertension, and liver disease, along with the associated treat-
ments necessary to address these potential conditions, it would 
appear that all individuals with ARPKD are at significant risk 
for neurocognitive impairments—even with relatively successful 
treatments of these conditions. When these medical condi-
tions are overlaid on the observations that these challenges are 
occurring during critical periods of early brain development, the 
risk for neurocognitive dysfunctions is heightened to a greater 
degree. Despite these significant risk factors for neurocognitive 
outcomes, there is a paucity of literature addressing neurocogni-
tion in children with ARPKD. There have been several case series 
presentations describing children with ARPKD (37, 38); however, 
despite what appears to be significant risk for neurocognitive 
impairment in this population, there are virtually no empirically 
based studies examining the neurocognitive functioning in chil-
dren with ARPKD.
To our knowledge, there has been only one systematic inves-
tigation of neurocognition in children with ARPKD (39). This 
study examined results of comprehensive neurocognitive assess-
ments in children with ARPKD in the chronic kidney disease 
in children (CKiD) cohort study, a multicenter investigation 
of children with mild-to-moderate CKD. To look for disease-
specific neurocognitive effects of ARPKD, children with ARPKD 
were compared to a control group of children with renal aplasia/
hypoplasia/dysplasia who were matched based on kidney func-
tion, age at study entry, and age at diagnosis. In all domains 
evaluated, which included intellectual functioning, academic 
achievement, attention regulation, executive functioning, and 
behavior, children with ARPKD performed comparably to the 
control group in this cohort. Both groups had scores within the 
average range in all domains, but a larger than expected propor-
tion of children in both groups had scores in the “at-risk” range 
(i.e., worse than 1 SD below the mean) in some domains. These 
findings were consistent with prior studies of neurocognition in 
children with mild-to-moderate CKD (16). While these results 
are somewhat reassuring, they may not be generalizable to 
children with more severe manifestations of ARPKD given that 
the CKiD study only included children with mild-to-moderate 
CKD. Further studies examining the neurocognitive and social– 
behavioral functioning in children with ARPKD are sorely 
needed, with particular attention being devoted to improving our 
knowledge of the genotype–phenotype linkages for this single 
gene disorder.
CHALLenGeS AnD FUTURe DiReCTiOnS 
FOR ARPKD
Clinical Best Practices
The meager literature suggests that children with ARPKD may 
not manifest neurocognitive difficulties; however, in addition to 
the limitations of the available literature and the medical risk 
factors present in all of these individuals, it is likely that chil-
dren with ARPKD are at elevated risk for neuropsychological 
difficulties. Yet, the extant literature provides scant information 
to explicitly guide clinical practice with this population. Given 
the complexity of the disease and the involvement of multiple 
providers, it will be critical for the clinical care team to review 
a child’s neuropsychological status on a systematic basis. Both 
structured (e.g., questionnaire) and unstructured (e.g., clinical 
interview) data from multiple sources (child, caregivers, and 
teachers) are likely to provide sufficient data to alert the medi-
cal team to cognitive, behavioral, or learning difficulties that 
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merit further assessment. Comprehensive neuropsychological 
assessment may be indicated for those children who show 
signs of learning and attention problems and for those who man-
ifest behavioral or emotional difficulties, the latter areas being 
particularly understudied in children with CKD and ARPKD 
more specifically. Given the at-risk status of this population, 
obtaining a baseline assessment for children whose neurocogni-
tive and psychosocial functioning appears relatively unaffected 
also will provide comparative data for when the child’s medical 
status and overall functioning begins to deteriorate. In addition 
to assisting in tracking developmental trajectories of various 
neurodevelopmental functions, such information is critical 
to the formation of developmentally appropriate intervention 
plans. These recommendations have been detailed via consensus 
expert recommendations provided by Guay-Woodford and col-
leagues (40).
Regardless of the assessment approach, an interdisciplinary 
team model is suggested (40–42). Ideally, the interdisciplinary 
team would include a consulting psychologist or neuropsycholo-
gist with specialized knowledge of CKD as well as the associated 
comorbid conditions (e.g., hypertension, liver disease), and 
the team would engage in systematic developmental surveil-
lance, perhaps via brief annual or biannual screenings, to track 
children’s cognitive, social, and behavioral functioning over 
time and/or in tandem with disease progression. Although the 
timing of a comprehensive evaluation will vary depending on an 
individual child’s risk factors, it is suggested that children with 
ARPKD who are showing neurocognitive or social–emotional 
problems and/or who have increasing medical risk secondary 
to the presence of comorbid conditions, receive more frequent 
evaluations, perhaps at key developmental transition points 
(i.e., before school entry, prior to middle school, transition to high 
school, etc.) so that developmentally appropriate interventions 
could be implemented. This interdisciplinary team approach 
has been suggested for other pediatric conditions (e.g., feeding 
disorders) (43) and its application to children with kidney disease 
should be explored.
Research
As can be seen from the above overview, there is a paucity of 
empirical findings pertaining to the neurocognitive and social–
emotional functioning of children with ARPKD. This is not an 
oversight by the field but, rather, a challenge to ascertain samples 
large enough to study. Indeed, additional case study and case series 
descriptions of the various neurocognitive and social–emotional 
manifestations of ARPKD would provide scientific discussion 
as to research directions for this population. This could be par-
ticularly important so as to describe functioning across different 
disease severity levels. Research on ARPKD is also complicated 
by the multiple avenues for morbidity that need to be concur-
rently addressed in any empirical study given the potential effects 
of these factors on children’s neurocognitive and psychosocial 
functioning.
Given the inherent overlap of these conditions with ARPKD, 
it may be useful for the field to capture such data from larger 
cohorts across CKD, liver disease, and hypertension populations. 
Consideration for the establishment of a national patient registry, 
perhaps via a large clinical research consortium, also may fuel 
ascertainment of patients for a myriad of scientific investigations, 
including the neurocognitive and social–emotional functioning 
of these children over the course of development. The ARegPKD, 
a European ARPKD Registry Study, has initiated such a project; 
however, it appears at this time that their rational, design, and 
study objectives do not include any formal measures of neuro-
cognition, neurodevelopment, or neurological functions (44). 
These latter features are critical to providing a comprehensive 
genotype–phenotype description of this complex genetic condi-
tion. As such, it will be critical for the field of pediatric nephrol-
ogy to continue to advance and refine the genotype–phenotype 
linkages so as to assist with the clinical developmental needs 
associated with this condition. This is particularly important 
given the early age of diagnosis for most of these cases (i.e., the 
importance of early intervention for the neurodevelopmental 
needs), the extended life expectancy that has been provided with 
ongoing medical advances (i.e., the increased challenges faced by 
older children, adolescents, and young adults with a multiorgan 
chronic illness), and the need for such assessment methods in 
future clinical trials to treat ARPKD.
COnCLUSiOn
This mini review provides an overview of the issues and chal-
lenges inherent in ARPKD, with a particular focus on the neu-
rocognitive functioning of this population. Despite the relative 
dearth of literature on the neurodevelopmental functioning 
and development of children with ARPKD, this type of kidney 
disease is associated with various factors that place children 
with ARPKD at risk for neurological and neuropsychological 
impairment. In particular, this mini review highlighted sev-
eral of the conditions that can accompany the kidney disease 
including hypertension, liver disease, and chronic lung disease. 
Additional complexities that can affect the cognitive and 
psychosocial functioning of this population include the need 
for an eventual kidney transplant, possible dual transplanta-
tion of the kidneys and liver, and associated medical needs, 
such as dialysis early in life for some of the more severely 
involved infants. Importantly, these factors are present during 
a critical period of brain development and not only contribute 
to proximal neurocognitive problems but also to possible dis-
tal, downstream neurocognitive problems over the course of 
development. Specific challenges and directions for the field of 
pediatric nephrology remain present for ARPKD, particularly 
with respect to advancing best clinical practices for profession-
als working with these children and guiding potential research 
directions for this rare condition.
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